NICM
DYN icon

Neo Ivy Capital Management’s Dyne Therapeutics DYN Stock Holding History

Neo Ivy Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06M Sell
168,753
-68,714
-29% -$1.18M 0.81% 25
2025
Q4 		$4.64M Buy
+237,467
New +$4.5M 0.73% 44
2025
Q1 		– Sell
-8,715
Closed -$205K – 324
2024
Q4 		$205K Buy
+8,715
New +$258K 0.04% 220

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Neo Ivy Capital Management's DYN Position: Q1 2026 in Review

Neo Ivy Capital Management reduced its Dyne Therapeutics (DYN) stake by 29% in Q1 2026, selling an estimated $1.18M and leaving 168,753 shares worth $3.06M. The position accounts for 0.81% of the portfolio, ranked #25.

Neo Ivy Capital Management first reported a position in DYN in Q4 2024 and has held it in 3 quarters since. The position peaked at $4.64M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Neo Ivy Capital Management held 168,753 shares of Dyne Therapeutics worth $3.06M as of Q1 2026.
  • Neo Ivy Capital Management sold 68,714 Dyne Therapeutics shares in Q1 2026, an estimated $1.18M.
  • Dyne Therapeutics made up 0.81% of Neo Ivy Capital Management's portfolio in Q1 2026, its #25 holding.
  • Neo Ivy Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Neo Ivy Capital Management's Dyne Therapeutics position peaked at $4.64M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.